Differential N‐ and O‐glycosylation signatures of HIV‐1 Gag virus‐like particles and coproduced extracellular vesicles
Open Access
- 10 February 2022
- journal article
- research article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (5) , 1207-1221
Abstract
Human immunodeficiency virus 1 (HIV‐1) virus‐like particles (VLPs) are nanostructures derived from the self‐assembly and cell budding of Gag polyprotein. Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response. In addition to this, the bounding membrane can be functionalized with exogenous antigens to target different diseases. Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response. One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs). In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N‐ and O‐ glycosylation profiles of Gag VLPs produced in HEK293 cells. We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP‐based vaccine production technology.Keywords
Funding Information
- European Molecular Biology Organization (Short‐Term Fellowship Number 8613)
- 'la Caixa' Foundation (LCF/BQ/ES17/11600003)
This publication has 68 references indexed in Scilit:
- Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-GlycansPLOS ONE, 2013
- Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virusGlycobiology, 2011
- The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral CladePLOS ONE, 2011
- The application of exosomes as a nanoscale cancer vaccineInternational Journal of Nanomedicine, 2010
- Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteinsNature Biotechnology, 2010
- Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigensProceedings of the National Academy of Sciences, 2010
- Glycosylation Patterns of HIV-1 gp120 Depend on the Type of Expressing Cells and Affect Antibody RecognitionJournal of Biological Chemistry, 2010
- Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing α-gal epitopesVaccine, 2010
- Engineered lentivector targeting of dendritic cells for in vivo immunizationNature Biotechnology, 2008
- Immunogenicity of Influenza Virus Vaccine Is Increased by Anti-Gal-Mediated Targeting to Antigen-Presenting CellsJournal of Virology, 2007